Journal of manipulative and physiological therapeutics · 2024
Photobiomodulation Therapy Effects at Different Stages of the Dystrophic Phenotype: A Histomorphometric Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Covatti Caroline, Mizobuti Daniela Sayuri, da Rocha Guilherme Luiz, da Silva Heloina Nathalliê Mariano, Minatel Elaine
Аннотация
OBJECTIVE: The purpose of this study was to evaluate the effects of photobiomodulation therapy (PBMT) on the gastrocnemius muscle of X-linked muscular dystrophy (mdx) mice.
METHODS: The study used an experimental model of Duchenne muscular dystrophy, at 3 stages of degeneration/regeneration of muscle fibers: an acute stage (14-28 days old), acute and stabilized stages (14-42 days old), and a stabilized stage (28-42 days old). Photobiomodulation therapy (also known as low-level light therapy) at 0.6 J was applied 3 times per week to the dystrophic gastrocnemius muscle of mdx mice at ages 14 to 28, 14 to 42, and 28 to 42 days. After the treatment period, the gastrocnemius muscle was collected, and cryosections were prepared for histopathologic analysis.
RESULTS: In all 3 stages evaluated, a significant reduction was observed in immunoglobulin G uptake by muscle fibers, the inflammatory area, macrophage infiltration, the reactive dihydroethidium area, and the number of autofluorescent lipofuscin granules in the gastrocnemius muscle of mdx mice after PBMT.
CONCLUSION: The results demonstrated that low-level light therapy, when applied during or after the acute phase of the degeneration/regeneration muscle process, improves the pathological histomorphologic features in dystrophic muscle. Based on these results, PBMT appears to be a promising therapy for dystrophinopathies, warranting further research in humans to verify its efficacy.
METHODS: The study used an experimental model of Duchenne muscular dystrophy, at 3 stages of degeneration/regeneration of muscle fibers: an acute stage (14-28 days old), acute and stabilized stages (14-42 days old), and a stabilized stage (28-42 days old). Photobiomodulation therapy (also known as low-level light therapy) at 0.6 J was applied 3 times per week to the dystrophic gastrocnemius muscle of mdx mice at ages 14 to 28, 14 to 42, and 28 to 42 days. After the treatment period, the gastrocnemius muscle was collected, and cryosections were prepared for histopathologic analysis.
RESULTS: In all 3 stages evaluated, a significant reduction was observed in immunoglobulin G uptake by muscle fibers, the inflammatory area, macrophage infiltration, the reactive dihydroethidium area, and the number of autofluorescent lipofuscin granules in the gastrocnemius muscle of mdx mice after PBMT.
CONCLUSION: The results demonstrated that low-level light therapy, when applied during or after the acute phase of the degeneration/regeneration muscle process, improves the pathological histomorphologic features in dystrophic muscle. Based on these results, PBMT appears to be a promising therapy for dystrophinopathies, warranting further research in humans to verify its efficacy.